This paper is only available as a PDF. To read, Please Download here.
A total of 113 laboratory workers, whose history of contact with monkeys or monkey tissues ranged from 0 to 30 years, were tested for herpes simplex virus (HSV) and B virus (BV) neutralising antibodies. Eighty-three per cent of them were positive for HSV antibody and 69 per cent were positive for BV antibody. Of the 35 persons negative for BV antibody, 18 were also negative for HSV antibody. There was no difference in the rate of either antibody between males and females, but a distinct increase in the rates and levels of both was noted with increase in age. No significant correlation could be established between, the rate of presence of BV antibody and duration of contact with monkeys or their tissues. In only one instance was BV antibody detected, and that in low level, in a person with no HSV antibody. This man had been working with monkeys for less than 1 year. In all other cases, BV antibody occurred only when HSV antibody was also present, and a striking correlation was noted between the levels of the two antibodies: BV antibody was absent when HSV antibody was absent or had a geometric mean titer of 1:22; its mean rose to 1:7 when that of HSV was 1:48, and to 1:24 when that of HSV was 1:88. HSV antibody levels were also higher than those of BV in 3 of 4 commercial lots of human gamma globulin of placental origin, although the reverse was true of the fourth lot. The levels of BV antibody of five experimental lots of gamma globulin from monkeys, prepared by the same procedure and to the same protein concentration, were comparable to those of gamma globulin from humans. The implications of these findings with regard to the protection of man against accidental infection with BV have been discussed.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Translational Research
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- The relationship of herpes and B. viruses: Immunological and epidemiological considerations.Australian J. Exper. Biol. 1939; 17: 41
- Studies on the B virus. I. The immunological identity of a virus isolated from a human case of ascending myelitis associated with visceral necrosis.Brit. J. Exper. Path. 1934; 15: 248
- B virus: Its current significance. Description and diagnosis of a fatal human infection.Am. J. Hyg. 1958; 68: 242
- A fatal B virus infection in a person subject to recurrent herpes labialis.Canad. M. A. J. 1958; 79: 743
- Isolation of B virus (herpes group) from the central nervous system of a rhesus monkey.J. Exper. Med. 1954; 100: 181
- Neutralizing antibodies in human sera to Herpesvirus simiae (B virus).Texas Rep. Biol. & Med. 1961; 19: 376
- Virus adsorption and plaque formation in monolayer cultures of trypsin-dispersed monkey kidney.J. Immunol. 1956; 76: 288
- Immunization against B virus infection. II. Further laboratory and clinical studies with an experimental vaccine.Am. J. Hyg. 1962; 76: 239
- Occupational infection with virus B of monkeys.J. A. M. A. 1962; 179: 804
- “B” virus disease in monkey and man.Brit. Vet. J. 1966; 122: 46
- The specific amino acid requirements of a human carcinoma cell (strain HeLa) in tissue culture.J. Exper. Med. 1955; 102: 37
- A simple method of estimating 50 per cent end points.Am. J. Hyg. 1938; 27: 493
- Statistical methods applied to experiments in agriculture and biology.ed. 5. The Iowa State College Press, Ames, Iowa1956 (chap. 14)
- Pan American Health Organization, Washington, D. CNov. 7–11, 1966 International Conference on Vaccines Against Viral and Rickettsial Diseases of Man.
Accepted: March 23, 1967
Received: February 25, 1967
© 1967 Published by Elsevier Inc.